Vanguard Fiduciary Trust
HAE icon

Vanguard Fiduciary Trust’s Haemonetics HAE Stock Holding History

Vanguard Fiduciary Trust’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Buy
330,398
+6,813
+2% +$438K 0.01% 1294
2026
Q1 		$18.2M Buy
+323,585
New +$21.1M ﹤0.01% 1383

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's HAE Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Haemonetics (HAE) stake by 2.1% in Q2 2026, buying an estimated $438K and bringing the position to 330,398 shares worth $24.8M. The position accounts for 0.01% of the portfolio, ranked #1294.

Vanguard Fiduciary Trust first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Vanguard Fiduciary Trust held 330,398 shares of Haemonetics worth $24.8M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 6,813 Haemonetics shares in Q2 2026, an estimated $438K.
  • Haemonetics made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1294 holding.
  • Vanguard Fiduciary Trust first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
  • 327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.